Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobumichi Tanaka

Showing results (31-40 of 290) with videos related to

Pageof 29
Sort By:
World Journal of Urology|January 4, 2015
Estimated functional renal parenchymal volume predicts the split renal function following renal surgeryHisakazu Mibu, Nobumichi Tanaka, Yukinari Hosokawa, et al.
Urology|February 15, 2011
Relationship between nocturnal urine volume, leg edema, and urinary antidiuretic hormone in older menAkihide Hirayama, Kazumasa Torimoto, Astushi Yamada, et al.
Radiation Oncology (London, England)|February 1, 2013
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyNobumichi Tanaka, Isao Asakawa, Satoshi Anai, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|February 26, 2004
[Metachronous bilateral ureteral cancer in patient with hereditaly nonpolyposis colorectal cancer]Masashi Yamamoto, Hiroki Kashiwai, Naoya Hirata, et al.
BMC Cancer|December 12, 2013
Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009Nobumichi Tanaka, Akihide Hirayama, Tatsuo Yoneda, et al.
BMC Urology|January 8, 2013
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft modelTakeshi Inoue, Satoshi Anai, Sayuri Onishi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|April 17, 2008
[Bilateral adrenal metastases from renal cell carcinoma: a case report]Atsushi Yamada, Masahiro Tanaka, Motokiyo Yoshikawa, et al.
BMC Urology|September 15, 2012
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancerNobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, et al.
The Prostate|May 12, 2024
Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matchingYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
BMC Cancer|September 4, 2017
Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012Nobumichi Tanaka, Yasushi Nakai, Makito Miyake, et al.
Pageof 29

Showing results (31-40 of 290) with videos related to

Sort By:
Pageof 29
World Journal of Urology|January 4, 2015
Estimated functional renal parenchymal volume predicts the split renal function following renal surgeryHisakazu Mibu, Nobumichi Tanaka, Yukinari Hosokawa, et al.
Urology|February 15, 2011
Relationship between nocturnal urine volume, leg edema, and urinary antidiuretic hormone in older menAkihide Hirayama, Kazumasa Torimoto, Astushi Yamada, et al.
Radiation Oncology (London, England)|February 1, 2013
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyNobumichi Tanaka, Isao Asakawa, Satoshi Anai, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|February 26, 2004
[Metachronous bilateral ureteral cancer in patient with hereditaly nonpolyposis colorectal cancer]Masashi Yamamoto, Hiroki Kashiwai, Naoya Hirata, et al.
BMC Cancer|December 12, 2013
Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009Nobumichi Tanaka, Akihide Hirayama, Tatsuo Yoneda, et al.
BMC Urology|January 8, 2013
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft modelTakeshi Inoue, Satoshi Anai, Sayuri Onishi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|April 17, 2008
[Bilateral adrenal metastases from renal cell carcinoma: a case report]Atsushi Yamada, Masahiro Tanaka, Motokiyo Yoshikawa, et al.
BMC Urology|September 15, 2012
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancerNobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, et al.
The Prostate|May 12, 2024
Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matchingYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
BMC Cancer|September 4, 2017
Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012Nobumichi Tanaka, Yasushi Nakai, Makito Miyake, et al.
Pageof 29